Sobi Canada Inc.
1155 North Service Road West
About Sobi Canada Inc.Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (CAD 514 million) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ Stockholm.
November 1, 2015
Please click here for Sobi Canada job opportunities.
13 articles about Sobi Canada Inc.
Annals of Rheumatic Diseases Publishes Results from Phase 2 Study of emapalumab in Patients with Secondary HLH/Macrophage Activation Syndrome
Sobi North America announced that the Annals of Rheumatic Diseases has published results from an open-label, single-arm, multicenter phase 2 study evaluating the safety and efficacy of emapalumab, an anti-interferon-gamma monoclonal antibody, being investigated in patients with sJIA or AOSD who developed sHLH/Macrophage Activation Syndrome following an inadequate response to high-dose glucocorticosteroids.
Clinical Catch-Up for July 8-12
7/15/2019It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
Extended Half-Life Prophylaxis Improves Quality of Life in Hemophilia Patients, Study Shows
7/9/2019The introduction of EHLs allowed hemophilia patients to live a life beyond their disease, with improved quality of life, the study showed.
Sobi Presents Study Data Supporting Increased Possibilities and Improved Clinical Outcomes for People With Haemophilia at ISTH
It will be the first time interim results from the global, prospective verITI-8 study of rFVIIIFc for first-time ITI will be presented.
Sobi Presents Update on State of Newborn Screening for HT-1 in the United States at APHL 2019 Newborn Screening and Genetic Testing Symposium
Newborn screening is essential to rapid diagnosis of HT-1
Sobi to Showcase Latest Rare Disease and Specialty Care Research at Multiple Spring 2019 Scientific Meetings
Sobi announced that investigators will present data from across its rare disease and specialty care portfolio at multiple scientific meetings this Spring.
Sobi and Novimmune Selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)
Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders for the 2019 Rare Impact Awards.
FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)
Primary HLH is an ultra-rare syndrome of hyper-inflammation that usually occurs within the first year of life and can rapidly become lethal unless diagnosed and treated
Biotech Movers and Shakers Aug. 27
8/27/2018Who made a splash in the biotech world this week? Here are some notable people.
Sobi Names Jeff Henderson Vice President, Head of Market Access and Government Affairs, U.S.
Henderson will build the Sobi patient access team in the U.S.
Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin® (nitisinone) for the Treatment of HT-1
- First and only nitisinone product in Canada approved for once-daily use, designed to meet the needs of HT-1 patients entering older childhood, adolescence and adulthood -
Sobi’s Orfadin® (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee
Sobi intends to continue taking the necessary steps to ensure Orfadin remains accessible to Canadian patients.
Sobi Canada Release: Health Canada Approves Orfadin Capsules For Treatment Of Hereditary Tyrosinaemia Type-1 (HT-1)